{"version":"1.0","provider_name":"TRI-Genotoul","provider_url":"https:\/\/trigenotoul.com\/en","author_name":"gesteve","author_url":"https:\/\/trigenotoul.com\/en\/author\/gesteve\/","title":"Partenariat ROCHE : L'imagerie en appui de l'immunoth\u00e9rapie du cancer - TRI-Genotoul","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"IjVHdGhQAD\"><a href=\"https:\/\/trigenotoul.com\/en\/partenariat-roche-limagerie-en-appui-de-limmunotherapie-du-cancer\/\">ROCHE Partnership: Imaging supporting cancer immunotherapy<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/trigenotoul.com\/en\/partenariat-roche-limagerie-en-appui-de-limmunotherapie-du-cancer\/embed\/#?secret=IjVHdGhQAD\" width=\"600\" height=\"338\" title=\"&#8220;Partenariat ROCHE : L&rsquo;imagerie en appui de l&rsquo;immunoth\u00e9rapie du cancer&#8221; &#8212; TRI-Genotoul\" data-secret=\"IjVHdGhQAD\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/trigenotoul.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/trigenotoul.com\/wp-content\/uploads\/2018\/01\/noued-lymphatique-intravital-1.jpg","thumbnail_width":730,"thumbnail_height":730,"description":"Le laboratoire pharmaceutique Roche et l\u2019Institut de Pharmacologie et de Biologie Structurale (IPBS) partagent l&rsquo;objectif de d\u00e9velopper des strat\u00e9gies de lutte contre le cancer. Alors que Roche est un acteur majeur dans le d\u00e9veloppement de strat\u00e9gies d\u2019immunoth\u00e9rapie, les travaux de recherche de l\u2019IPBS visent \u00e0 identifier et caract\u00e9riser de nouvelles cibles th\u00e9rapeutiques dans le domaine [&hellip;]"}